SGC-CK2-1
Based on 5 publication(s) in Google Scholar
SGC-CK2-1 is a highly potent, ATP-competitive, and cell-active CK2 chemical probe with exclusive selectivity for both human CK2 isoforms, with IC50s of 36 and 16 nM for CK2α and CK2α′respectively in the nanoBRET assay. SGC-CK2-1 can be used for the research of neurodegenerative diseases.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.87%
- CAS No.: 2470424-39-4
- Formule: C20H21N7O
- Masse moléculaire:375.43
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Publications Citing Use of MedChemExpress (MCE) SGC-CK2-1
More
Activité biologique
|
CK2α 36 nM (IC50) |
CK2α' 16 nM (IC50) |
SGC-CK2-1 inhibits CSNK2A2 and CSNK2A1 with IC50s value of 2.3 and 4.2 nM[1].
SGC-CK2-1 inhibits DYRK2 with the IC50 value of 3.7 μM[1].
SGC-CK2-1 inhibits blood U-937, MV4-11, MOLM-13, OCI-LY19, OCI-AML5 cells with IC50s of 120, 690, 750, 760 and 810 nM, respectively. SGC-CK2-1 inhibits Head/Neck Detroit562 cells with an IC50 of 550 nM. SGC-CK2-1 inhibits Lung NCI-H2286 cells with an IC50 of 550 nM. SGC-CK2-1 inhibits Brain SK-N-MC cells with an IC50 of 730 nM. SGC-CK2-1 inhibits Breast BT-20 cells with an IC50 of 810 nM. SGC-CK2-1 inhibits Skin A375 cells with an IC50 of 830 nM. SGC-CK2-1 inhibits Stomach SNU-1 cells with an IC50 of 860 nM. SGC-CK2-1 inhibits Duodenum Hutu 80 cells with an IC50 of 920 nM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 2470424-39-4
-
Appearance Solid
-
Masse moléculaire 375.43
-
Formule C20H21N7O
-
Color Off-white to light yellow
-
SMILES
CCC(NC1=CC(NC2=NC3=C(C#N)C=NN3C(NC4CC4)=C2)=CC=C1C)=O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (5)
-
Journal Impact Factor
-
Most Recent
-
Int J Biol Macromol
Critical role of protein kinase CK2 in chronic myeloid leukemia cells harboring the T315I BCR::ABL1 mutation. [Abstract]2025 Jan:286:138305. PMID: 39631575 -
FASEB J
A Novel Dysferlin-Binding Kinase CK2α Promotes Plasma Membrane Repair in Dysferlinopathy. [Abstract]2026 Mar 31;40(6):e71677. PMID: 41824290 -
ACS Chem Biol
Targeted O-GlcNAcylation of CK2α Triggers Its Ubiquitin-Proteasome Degradation and Alters Downstream Phosphorylation. [Abstract]2025 Jul 18;20(7):1646-1659. PMID: 40521680 -
Open Biol
Analysis of the phosphoproteome of CK2 α(-/-)/Δ α' C2C12 myoblasts compared to the wild-type cells. [Abstract]2023 Feb;13(2):220220. PMID: 36809799 -
Solvant et solubilité
DMSO : 100 mg/mL (266.36 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.66 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (276 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Carrow I Wells, et al. Development of a potent and selective chemical probe for the pleiotropic kinase CK2. Cell Chem Biol. 2021 Apr 15;28(4):546-558.e10. [Content Brief]
[2]. Marco P Licciardello, et al. A New Chemical Probe Challenges the Broad Cancer Essentiality of CK2. Trends Pharmacol Sci. 2021 May;42(5):313-315. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.6636 mL | 13.3181 mL | 26.6361 mL | 66.5903 mL |
| 5 mM | 0.5327 mL | 2.6636 mL | 5.3272 mL | 13.3181 mL | |
| 10 mM | 0.2664 mL | 1.3318 mL | 2.6636 mL | 6.6590 mL | |
| 15 mM | 0.1776 mL | 0.8879 mL | 1.7757 mL | 4.4394 mL | |
| 20 mM | 0.1332 mL | 0.6659 mL | 1.3318 mL | 3.3295 mL | |
| 25 mM | 0.1065 mL | 0.5327 mL | 1.0654 mL | 2.6636 mL | |
| 30 mM | 0.0888 mL | 0.4439 mL | 0.8879 mL | 2.2197 mL | |
| 40 mM | 0.0666 mL | 0.3330 mL | 0.6659 mL | 1.6648 mL | |
| 50 mM | 0.0533 mL | 0.2664 mL | 0.5327 mL | 1.3318 mL | |
| 60 mM | 0.0444 mL | 0.2220 mL | 0.4439 mL | 1.1098 mL | |
| 80 mM | 0.0333 mL | 0.1665 mL | 0.3330 mL | 0.8324 mL | |
| 100 mM | 0.0266 mL | 0.1332 mL | 0.2664 mL | 0.6659 mL |